Qritive Market Research Report

Company Overview

Name and Mission

Company Name: Qritive Pte. Ltd.

Mission: Qritive develops clinical-grade AI-powered solutions to support pathologists in every step of the way, helping them to optimize patient outcomes and advance disease care for debilitating conditions like cancer.

Founding Information

Founded: No information is available.

Founders: Aneesh Sathe and Kaveh Taghipour.

Key People

No information is available on other key people in the company.

Headquarters

Location: Singapore.

Number of Employees

No information is available.

Revenue

No information is available.

Known For

Qritive is known for leveraging the power of AI to advance pathology, focusing on supporting pathologists and providing patient-centric care for improved health outcomes.

Products

Qritive Platform

High-Level Description: An intuitive AI-powered ecosystem that digitizes the entire workflow for pathologists, enabling remote diagnosis and telepathology.

Key Features:

AI-driven analysis of whole slide images.

Vendor-agnostic integration with major LIS, EMR, and hospital information systems.

A comprehensive dashboard for case management and workflow.

A user-friendly whole-slide image viewer.

PantheonTM

High-Level Description: An AI-driven ecosystem transforming pathology, designed to streamline the workflow for pathologists.

Key Features:

Clinically approved and vendor-agnostic.

Equipped to support case management, AI analysis, and report generation.

Compatible with PACS systems and DICOM protocol.

Offers security and compliance with international standards.

QAi Prostate Dx and QAi Prostate Grade

High-Level Description: Advanced AI-powered solutions for prostate cancer screening and grading.

Key Features:

AI-based tumor classification and segmentation.

Provides detailed AI-driven insights for pathologists.

Generates comprehensive summary reports for prostate anatomy and tumor classification.

Recent Developments

New Products and Features

Collaboration with Roche: Qritive joined forces with Roche to redefine global cancer diagnostics using AI (September 12, 2024).

ISO/IEC 27001:2022 Certification: Achieved certification for information security management standards (July 10, 2024).

Class C IVD Certification: QAi Prostate Dx module received Class C IVD certification from the Health Sciences Authority (March 18, 2024).

Partnerships

Roche Partnership: Qritive collaborated with Roche, enhancing its capacities and global outreach.

Participation in MedTech Innovator Asia Pacific Accelerator 2024 Program: Selected among the top 20 companies for this prestigious program.

Events

Participation in Singapore Innovation Week in Los Angeles (July 2, 2024): Highlighted involvement in digital pathology innovations.

Award from ISBP-BCRF for Breast Pathology Research (April 8, 2024): Recognized for excellence in breast pathology research.

Conclusion

This report offers a structured overview of Qritive, focusing on the available data. Qritive is prominently positioned in the field of digital pathology with innovative AI-powered solutions, ongoing partnerships, and recent achievements in regulatory certifications. The company is faithful to its mission of enhancing pathology through AI innovations to improve patient outcomes, making significant strides globally in collaboration with industry giants such as Roche.